Scopus:
Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves

dc.contributor.authorCorum O.
dc.contributor.authorYildiz R.
dc.contributor.authorIder M.
dc.contributor.authorAltan F.
dc.contributor.authorOk M.
dc.contributor.authorUney K.
dc.date.accessioned2023-04-12T01:40:10Z
dc.date.available2023-04-12T01:40:10Z
dc.date.issued2019-11-01
dc.description.abstractThe aim of this study was to evaluate the pharmacokinetics and bioavailability of cefquinome (CFQ) and ceftriaxone (CTX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. Using a parallel design, 24 premature calves were randomly divided into the two antibiotic groups. Each of the six animals in the first group received CFQ (2 mg/kg) through IV or IM administration. The second group received CTX (20 mg/kg) via the same administration route. Plasma concentrations of the drugs were analyzed by high-performance liquid chromatography and noncompartmental methods. Mean pharmacokinetic parameters of CFQ and CTX following IV administration were as follows: elimination half-life (t1/2λz) 1.85 and 3.31 hr, area under the plasma concentration–time curve (AUC0–∞) 15.74 and 174 hr * μg/ml, volume of distribution at steady-state 0.37 and 0.45 L/kg, and total body clearance 0.13 and 0.12 L hr−1 kg−1, respectively. Mean pharmacokinetic parameters of CFQ and CTX after IM injection were as follows: peak concentration 4.56 and 25.04 μg/ml, time to reach peak concentration 1 and 1.5 hr, t1/2λz 4.74 and 3.62 hr, and AUC0–∞ 22.75 and 147 hr * μg/ml, respectively. The bioavailability of CFQ and CTX after IM injection was 141% and 79%, respectively. IM administration of CFQ (2 mg/kg) and CTX (20 mg/kg) can be recommended at 12-hr interval for treating infections caused by susceptible bacteria, with minimum inhibitory concentration values of ≤0.5 and ≤4 μg/ml, respectively, in premature calves. However, further research is indicated to assess the pharmacokinetic parameters following multiple doses of the drug in premature calves.
dc.identifier.doi10.1111/jvp.12789
dc.identifier.issn01407783
dc.identifier.pubmed31197850
dc.identifier.scopus2-s2.0-85067614931
dc.identifier.urihttps://hdl.handle.net/20.500.12597/4974
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.rightsfalse
dc.subjectbioavailability | cefquinome | ceftriaxone | pharmacokinetics | premature calves
dc.titlePharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves
dc.typeArticle
dspace.entity.typeScopus
oaire.citation.issue6
oaire.citation.volume42
person.affiliation.nameKastamonu University
person.affiliation.nameMehmet Akif Ersoy Üniversity
person.affiliation.nameSelçuk Üniversitesi
person.affiliation.nameDicle Üniversitesi
person.affiliation.nameSelçuk Üniversitesi
person.affiliation.nameSelçuk Üniversitesi
person.identifier.orcid0000-0003-3168-2510
person.identifier.orcid0000-0002-9017-763X
person.identifier.orcid0000-0002-8674-4873
person.identifier.scopus-author-id55902904600
person.identifier.scopus-author-id15756686000
person.identifier.scopus-author-id57078919700
person.identifier.scopus-author-id26433107400
person.identifier.scopus-author-id6701698266
person.identifier.scopus-author-id8408064700
relation.isPublicationOfScopus2c73da40-e666-402d-87a2-277292493dbd
relation.isPublicationOfScopus.latestForDiscovery2c73da40-e666-402d-87a2-277292493dbd

Files